Research programme: zidovudine stem cell therapeutics - ZGene/Karolinska Institute
Latest Information Update: 09 Oct 2014
At a glance
- Originator Karolinska Institute; ZGene
- Class Cell therapies
- Mechanism of Action DNA-directed DNA polymerase inhibitors; Nucleotide reverse transcriptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer